Nothing Special   »   [go: up one dir, main page]

WO2022125006A1 - Compositions de favipiravir à charge médicamenteuse élevée - Google Patents

Compositions de favipiravir à charge médicamenteuse élevée Download PDF

Info

Publication number
WO2022125006A1
WO2022125006A1 PCT/TR2020/051259 TR2020051259W WO2022125006A1 WO 2022125006 A1 WO2022125006 A1 WO 2022125006A1 TR 2020051259 W TR2020051259 W TR 2020051259W WO 2022125006 A1 WO2022125006 A1 WO 2022125006A1
Authority
WO
WIPO (PCT)
Prior art keywords
favipiravir
drug load
high drug
immediate release
pharmaceutical composition
Prior art date
Application number
PCT/TR2020/051259
Other languages
English (en)
Inventor
Erol KIRESEPI
Ersin Yildirim
Original Assignee
Santa Farma Ilac Sanayii A.S.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santa Farma Ilac Sanayii A.S. filed Critical Santa Farma Ilac Sanayii A.S.
Priority to EP20965250.2A priority Critical patent/EP4259141A4/fr
Priority to PCT/TR2020/051259 priority patent/WO2022125006A1/fr
Publication of WO2022125006A1 publication Critical patent/WO2022125006A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses

Definitions

  • the present invention relates to high drug load oral pharmaceutical compositions comprising Favipiravir or its pharmaceutically acceptable salt thereof manufactured by using wet granulation method.
  • Favipiravir its chemical name is 6-Fluoro-3-hydroxy-2-pyrazinecarboxamide, is an anti-viral agent that selectively and potently inhibits RNA dependent RNA polymerase (RdRP), which are necessary for the transcription and replication of viral genomes.
  • RdRP RNA dependent RNA polymerase
  • the empirical formula of Favipiravir is C 5 H 4 FN 3 O 2 and molecular weight is 157.104 g/mole.
  • Favipiravir is a white to light yellow powder. It is not hygroscopic at 25°C/51% to 93%RH and is sparingly soluble in acetonitrile and in methanol and slightly soluble in water and in ethanol. It is slightly soluble at pH 2.0 to 5.5 and sparingly soluble at pH 5.5 to 6.
  • Favipiravir and its pharmaceutically acceptable salts first have been declared in EPl 112743 by Toyama Chemical Co. Ltd who discovered through screening chemical library for anti-viral activity against the influenza virus.
  • Favipiravir was first commercially authorized in Japan to treat cases of influenza that were unresponsive to conventional treatment.
  • Favipiravir The innovative product of Favipiravir is currently in the form of tablet form under the name AVIGAN ® in the strength of 200 mg in worldwide. Favipiravir is indicated for the treatment of novel or re-emerging influenza virus infections and also has shown anti-viral activity even against amantadine, oseltamivir and zanamivir resistant influenza viruses in vitro like COVID- 19.
  • the recommended term of Favipiravir treatment is 5 -day at the beginning period of its use in COVID-19 treatment.
  • the new publications and clinical studies have shown that the term of Favipiravir treatment may be longer for a comprehensive recovery up to 14 days.
  • the usual recommended dose of Favipiravir is 1600 mg orally twice daily in the first day of treatment and followed by 600 mg orally twice daily for four days. These doses are administered in two equal amounts daily.
  • the recommended total administration period should be at least five days.
  • the daily administered dose is very high.
  • AVIGAN ® 200 mg Tablet to be administered daily, in the first day is 18 and this number is 6 on the following four days.
  • AVIGAN ® is in the form of film-coated tablet contains Favipiravir as active ingredient and povidone, colloidal silicon dioxide, low-substituted hydroxypropyl cellulose, crospovidone, sodium stearyl fumarate, hypromellose, titanium dioxide, talc and yellow ferric oxide as pharmaceutically acceptable excipients.
  • Favipiravir is well absorbed orally with bioavailability of approximately 97.6%, plasma protein binding of 54%. Favipiravir is not metabolized by cytochrome P-450 (CYP) enzyme. It is metabolized in liver mostly by aldehyde oxidase and partly to a hydroxylated form by xanthine oxidase. It is excreted in hydroxylated form by kidneys.
  • CYP cytochrome P-450
  • EP2407166 relates to a pharmaceutical composition
  • a pharmaceutical composition comprising Favipiravir or pharmaceutically acceptable salt thereof, a low substituted hydroxypropyl cellulose or croscarmellose sodium and a binder manufactured by a fluidized bed granulation method wherein Favipiravir contained is 50 to 95% of the mass of the tablet or the granulated powder.
  • EP2623493 relates to a pharmaceutical composition
  • a pharmaceutical composition comprising Favipiravir or pharmaceutically acceptable thereof wherein Favipiravir is in the salt of meglumine salt for the development of an injectable preparation with superior solubility.
  • CN111450063 relates to a pharmaceutical composition
  • a pharmaceutical composition comprising Favipiravir or pharmaceutically acceptable thereof wherein the prepared granulation contains Favipiravir, filler, suspending agent, sweetener, glidant, and pH regulator wherein Favipiravir has a particle size volume distribution with a D90 less than 40 microns.
  • CN107737128 relates to a pharmaceutical composition
  • a pharmaceutical composition comprising Favipiravir or pharmaceutically acceptable thereof wherein the prepared granulation contains 200 mg Favipiravir, 24 to 45 mg microcrystalline cellulose, 10 to 18 mg lactose, 8 to 16 mg polyethylene glycol, 0.8 to 1.3 mg sodium lauryl sulfate, 2 to 5 mg fumed silica, and 1 to 2.5 mg magnesium stearate wherein Favipiravir has a particle size volume distribution with a D90 less than 40 microns and D50 between 26 and 33 microns.
  • CN 106667926 relates to a pharmaceutical composition comprising Favipiravir or pharmaceutically acceptable thereof wherein the prepared granulation contains Favipiravir, silicified microcrystalline cellulose and a binder.
  • the present invention relates to oral pharmaceutical compositions comprising Favipiravir or its pharmaceutically acceptable salt in high drug load and at least one pharmaceutically acceptable excipient as the immediate release dosage form manufactured by using wet granulation method with improved mechanical characteristics which reduces the number of daily administrations.
  • the object of this invention is to develop an immediate release composition comprising high and therapeutically effective amounts of Favipiravir or pharmaceutically acceptable salt thereof requiring high drug load in the composition used in the treatment of novel or re-emerging influenza virus infections like COVID-19.
  • the daily recommended administration dose of Favipiravir is very high although the present marketed available composition comprises 200 mg Favipiravir per tablet.
  • This administration is also recommended to be scheduled in twice daily which means 2 dosage forms of 800 mg could be administered in the morning and 2 dosage forms of 800 mg could be administered in the evening.
  • the patients continue to the treatment with only two administrations of 600 mg/dosage form daily for the following remaining duration of the treatment.
  • One dosage form of 600 mg can be administered in the morning and one dosage form of 600 mg can be administered in the evening.
  • the present invention relates to high drug load pharmaceutical composition comprising Favipiravir and its pharmaceutically acceptable salt in dose of 600 mg.
  • the present invention relates to high drug load pharmaceutical composition comprising Favipiravir and its pharmaceutically acceptable salt in dose of 800 mg.
  • Favipiravir or pharmaceutically acceptable salt thereof in a small size immediate release oral pharmaceutical compositions are possible for a given dose of Favipiravir which means between 70-80% by weight of the total composition.
  • the present invention relates to an immediate release composition comprising Favipiravir and at least one pharmaceutically acceptable excipient manufactured by using wet granulation process.
  • the present invention relates to an immediate release composition manufactured by using wet granulation method in which there are two phases named as intra-granular and extra-granular phases.
  • Another object of the present invention is to provide a preparation method of a pharmaceutical composition of Favipiravir wherein the pharmaceutical compositions herein disclosed can be manufactured into dosage forms, such as powder, granule, pellet, capsule, tablet, oral solution, oral suspension having desired dissolution profiles.
  • Another object of the present invention is to provide pharmaceutical compositions containing Favipiravir by using wet granulation process wherein provided for the manufacture of tablets containing the active ingredient, binder, diluent, disintegrants, glidant and lubricant wherein at least one excipient is present in both phases during manufacturing.
  • the present invention provides a pharmaceutical composition comprising high amounts of Favipiravir and at least one pharmaceutically acceptable excipient is developed in the immediate release dosage form with improved pharmaceutical characteristics.
  • the present invention is a pharmaceutical formulation contains a "high-load" of drug substance due to the relative large amount of drug substance needed for administration to patients.
  • high drug load means that the solid pharmaceutical formulation contains at least 50% by weight, calculated on the basis of the total weight of the formulation, of the active substance.
  • high drug load pharmaceutical composition is about patient compliance, because of the route of administration is oral swallowing a product with high total weight of the formulation is very difficult.
  • high drug load compositions have the highest therapeutically amount of active substance with design of low total weight of the formulation which makes the composition very dense.
  • the present invention is in immediate release form which means it should dissolve or disintegrate in the stomach within a short period of time and present rapid dissolution and absorption to produce rapid onset of action.
  • the granulation may be manufactured by the methods like direct compression, dry granulation or wet-granulation before tableting.
  • the selection of the manufacture process procedure depends on the physical and mechanical properties of the active ingredient and the excipients.
  • the mechanical properties of high drug load finished drug product are dominantly very similar to active ingredient as being the highest amount of ingredient in the total composition. Based on this information, the characterization of active ingredient should be performed intensively. For example, the flowability of powder blend behaves like a powder active ingredient alone. If the flowability of active ingredient is poor the compression and compaction processes could’t be performed successively which means characterization of active ingredient affects the quantitative and qualitative composition and the manufacturing method of finished drug product.
  • the solubility values should be minimum 800 mg/250 ml, 3.2 mg/ml to decide the active substance Favipiravir is in highly soluble class.
  • Favipiravir is assigned as highly soluble based on the Table-2, since all solubility values in various media are higher than the value of 3.2 mg/ml.
  • Favipiravir active substance Another physicochemical property flowability of Favipiravir active substance was identified by performing bulk density and tapped density properties. This analysis was performed according to the details declared in international guidelines.
  • the flowability is also effective in defining the proper manufacturing method.
  • High favipiravir load powder blend will have the flowability of favipiravir.
  • wet granulation refers to converting a powder blend into granules having suitable flow and cohesive properties for tableting.
  • the procedure consists of mixing the powders in a suitable blender followed by adding the granulation solution under shear to the mixed powders to complete the granulation process and get a granule to be mixed with other excipients required and to obtain a proper final blend for the compression process. This granulation and many mixing steps involved in wet granulation method will maintain to get a homogenous powder blend.
  • the present invention is to provide a pharmaceutical composition comprising favipiravir by using wet granulation method wherein the ingredients of the high drug load immediate release pharmaceutical composition include the active ingredient, release modifying agents, binders, disintegrant, plasticizer, lubricant, glidant, and granulation solvent selected as to be the most suitable excipients with respect to the intended form of administration.
  • the ingredients of the high drug load immediate release pharmaceutical composition include the active ingredient, release modifying agents, binders, disintegrant, plasticizer, lubricant, glidant, and granulation solvent selected as to be the most suitable excipients with respect to the intended form of administration.
  • the ingredients of the high drug load immediate release pharmaceutical composition include the active ingredient, release modifying agents, binders, disintegrant, plasticizer, lubricant, glidant, and granulation solvent selected as to be the most suitable excipients with respect to the intended form of administration.
  • the present invention are in the group comprising powder, granule, pellet, capsule
  • suitable fillers may comprise but not limited to dibasic calcium phosphate dehydrate, polysaccharides, primarily microcrystalline cellulose, lactose, mannitol, sugars, sorbitol, sucrose, inorganic salts, primarily calcium salts and the like and mixtures thereof.
  • the diluent is microcrystalline cellulose.
  • the pharmaceutical composition comprises at least a binder which can be selected from hypromellose, sodium carboxymethyl cellulose, cellulose or cellulose derivatives, povidone, starch, sucrose, polyethylene glycol, or mixtures thereof.
  • the binder is povidone.
  • the pharmaceutical composition comprises at least a disintegrant which can be selected from croscarmellose sodium, sodium starch glycolate, crospovidone, com starch, pregelatinized starch, low-substituted hydroxypropyl cellulose and microcrystalline cellulose.
  • a disintegrant which can be selected from croscarmellose sodium, sodium starch glycolate, crospovidone, com starch, pregelatinized starch, low-substituted hydroxypropyl cellulose and microcrystalline cellulose.
  • the disintegrants are crospovidone and pregelatinized starch.
  • the glidant is silicon dioxide.
  • the pharmaceutical composition comprises at least one lubricant which can be selected from sodium stearyl fumarate, magnesium stearate, calcium stearate talc, stearic acid and mixtures thereof.
  • the lubricant is sodium stearyl fumarate.
  • Wet granulation process relates to wet massing of the powder blend with a granulation fluid.
  • the composition of granulation fluid could be at least one excipient used as binder and a solvent to dissolve it or solely a solvent.
  • the granulating fluid contains a solvent which can be volatized easily, so that it can be removed by drying by not requiring high values of temperature.
  • the use of binder is used to ensure particle adhesion once the granule is dried. If the drying and subsequent handling is done in a proper conditions of manufacturing and the aggregates will maintain its integrity, the characterization of granule is both denser and more free flowing.
  • the overall process of wet granulation consists the manufacturing steps of weighing, powder blending, wet granulating, drying, milling/sieving, lubrication of the blend and compression.
  • the pharmaceutical composition comprises at least one granulation fluid which can be selected from deionized water, ethanol and isopropanol, either alone or in combination.
  • the granulation solvent is deionized water.
  • Example 1 Unit Formula of Example 1
  • Step (i) Favipiravir, Microcrystalline Cellulose and half amounts of Crospovidone and Pregelatinized Starch were screened through a proper sieve and transferred into high- shear mixer to stir, ii. Povidone was dissolved in a sufficient amount of deionized water till to dissolve completely, iii.
  • the solution in Step (ii) was added into the powder blend prepared in Step (i) to perform granulation process, iv.
  • the granules prepared in Step (iii) were dried in fluid bed dryer, v.
  • the dried prepared granules in Step (iv) were screened through a proper sieve and stirred, vi.
  • Example-1 Another important analytical test to evaluate the characterization of Example-1 was in-vitro dissolution study and the dissolution conditions were designated considering the gastrointestinal pathway of orally applied dosage forms.
  • volume of dissolution medium 900 ml

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des compositions pharmaceutiques orales à charge médicamenteuse élevée comprenant de la favipiravir ou son sel pharmaceutiquement acceptable, fabriquées en utilisant un procédé de granulation par voie humide.
PCT/TR2020/051259 2020-12-08 2020-12-08 Compositions de favipiravir à charge médicamenteuse élevée WO2022125006A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP20965250.2A EP4259141A4 (fr) 2020-12-08 2020-12-08 Compositions de favipiravir à charge médicamenteuse élevée
PCT/TR2020/051259 WO2022125006A1 (fr) 2020-12-08 2020-12-08 Compositions de favipiravir à charge médicamenteuse élevée

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/TR2020/051259 WO2022125006A1 (fr) 2020-12-08 2020-12-08 Compositions de favipiravir à charge médicamenteuse élevée

Publications (1)

Publication Number Publication Date
WO2022125006A1 true WO2022125006A1 (fr) 2022-06-16

Family

ID=81974489

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2020/051259 WO2022125006A1 (fr) 2020-12-08 2020-12-08 Compositions de favipiravir à charge médicamenteuse élevée

Country Status (2)

Country Link
EP (1) EP4259141A4 (fr)
WO (1) WO2022125006A1 (fr)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106667926A (zh) * 2015-11-09 2017-05-17 石药集团中奇制药技术（石家庄）有限公司 一种法匹拉韦片剂及其制备方法
RU2731932C1 (ru) * 2020-05-07 2020-09-09 Общество с ограниченной ответственностью "Кромис" (ООО "Кромис") Противо-COVID-19 (SARS-CoV-2) вирусная фармацевтическая композиция

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG174291A1 (en) * 2009-03-13 2011-10-28 Toyama Chemical Co Ltd Tablet and granulated powder containing 6-fluoro-3-hydroxy-2-pyrazinecarboxamide
WO2022115055A1 (fr) * 2020-11-27 2022-06-02 Santa Farma Ilac Sanayii A.S. Composition à libération immédiate de favipiravir

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106667926A (zh) * 2015-11-09 2017-05-17 石药集团中奇制药技术（石家庄）有限公司 一种法匹拉韦片剂及其制备方法
RU2731932C1 (ru) * 2020-05-07 2020-09-09 Общество с ограниченной ответственностью "Кромис" (ООО "Кромис") Противо-COVID-19 (SARS-CoV-2) вирусная фармацевтическая композиция

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BAI, C. Q. ET AL.: "Clinical and virological characteristics of Ebola virus disease patients treated with favipiravir (T-705)-Sierra Leone, 2014", CLINICAL INFECTIOUS DISEASES, vol. 63, no. 10, 2016, pages 1288 - 1294, XP055951453 *
See also references of EP4259141A4 *

Also Published As

Publication number Publication date
EP4259141A1 (fr) 2023-10-18
EP4259141A4 (fr) 2024-09-11

Similar Documents

Publication Publication Date Title
RU2405540C1 (ru) Таблетка с высоким содержанием лекарственного препарата
AU2016272881C1 (en) Solid dosage forms of palbociclib
KR101699912B1 (ko) 1종 이상의 푸마르산 에스테르를 침식 매트릭스에 함유하는 제제
BR112020024107A2 (pt) combinação farmacêutica, composição, e preparação de combinação que compreende ativador de glucoquinase e inibidor de sglt-2 e métodos de preparação e uso dos mesmos
AU757547B2 (en) Novel compositions of eprosartan
JP2010536798A (ja) 難溶性薬物の生体利用率を制御するための方法及び組成物
WO2009140105A2 (fr) Préparations pour inhibiteurs de la cathepsine k
JP7428356B2 (ja) 高いバイオアベイラビリティを有するソラフェニブの医薬組成物、ソラフェニブ経口固形製剤、及びその使用
WO2013189305A1 (fr) Préparation solide d'un composé de valsartan-amlodipine et procédé de préparation associé
US20030022928A1 (en) Novel compositions of eprosartan
WO2022115055A1 (fr) Composition à libération immédiate de favipiravir
CN113633616A (zh) 一种生物利用度高的固体制剂
EP4058025A1 (fr) Compositions pharmaceutiques comprenant du ticagrelor
EP4259141A1 (fr) Compositions de favipiravir à charge médicamenteuse élevée
US20090030057A1 (en) Pharmaceutical composition of telmisartan
US11648242B2 (en) Pharmaceutical composition comprising pimavanserin, process of preparation and use thereof
US20230225977A1 (en) Formulation comprising daprodustat
JP6669937B2 (ja) ５−ｈｔ６拮抗薬の医薬組成物
WO2022042646A1 (fr) Composition de chlorhydrate de lurasidone et son procédé de préparation
KR102330953B1 (ko) 소듐-1-[6-(모르폴린-4-일)피리미딘-4-일]-4-(1h-1,2,3-트리아졸-1-일)-1h-피라졸-5-올레이트를 함유하는 제약 투여 형태
WO2018202224A1 (fr) Comprimés pelliculés de déférasirox
JP2019073488A (ja) アプレピタントを有効成分とする医薬錠剤
TW202435886A (zh) 米爾維仙(milvexian)醫藥組合物
WO2023080854A1 (fr) Compositions de chlorhydrate de lurasidone
WO2022036267A1 (fr) Compositions et méthodes de traitement

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20965250

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2020965250

Country of ref document: EP

Effective date: 20230710